Oxervate costs roughly $118,000 for a full eight-week treatment course, making it one of the most expensive eye medications on the market. That price tag comes down to a combination of factors: an ultra-rare patient population, complex manufacturing and storage requirements, no competing products, and regulatory protections that prevent generic alternatives from entering the market.
What Oxervate Costs Per Treatment
Each single-use vial of Oxervate carries a wholesale acquisition cost of about $2,111. Since treatment requires one vial per day for 56 consecutive days, the full course runs approximately $118,230. That’s the list price before insurance negotiation, but it sets the baseline for what insurers, pharmacies, and patients are working with.
To put that in perspective, most prescription eye drops cost between $50 and $500 per bottle and last weeks. Oxervate operates in an entirely different pricing tier because it isn’t a standard eye drop. It’s a recombinant human nerve growth factor, a biologic protein produced through genetic engineering rather than traditional chemical synthesis. Biologics are inherently more expensive to develop and manufacture than small-molecule drugs.
A Tiny Patient Population Drives the Price Up
Oxervate treats neurotrophic keratitis, a condition where the nerves supplying the cornea are damaged, leaving the surface of the eye unable to heal properly. It’s rare. Data from the American Academy of Ophthalmology’s IRIS Registry puts the prevalence at about 21 cases per 100,000 patients in the United States. That translates to a very small number of people who will ever need this drug.
This is the core economic reality behind the price. Pharmaceutical companies spread their development costs across every patient who uses the drug. When only a small fraction of the population has the condition, each patient’s share of those costs is dramatically higher. The company behind Oxervate, Dompé, funded two multinational clinical trials (REPARO and Study 0214) involving multiple countries and dozens of study sites to get the drug approved. Those trials demonstrated that patients receiving Oxervate were about six times more likely to achieve complete corneal healing at eight weeks compared to placebo. That’s strong clinical evidence, but generating it for a rare disease costs just as much as it would for a common one, with far fewer patients to recoup the investment.
Orphan Drug Exclusivity Blocks Competition
Oxervate received orphan drug designation from the FDA in June 2014 and marketing approval in August 2018. Orphan drug status, granted for conditions affecting fewer than 200,000 Americans, comes with a significant incentive: seven years of market exclusivity. During that window, the FDA will not approve another version of the same drug for the same condition. Oxervate’s exclusivity period runs through August 2025.
This means no biosimilar or generic competitor can legally enter the U.S. market until that date passes. Even after exclusivity expires, developing a biosimilar for a complex biologic protein is far more difficult and expensive than copying a standard pill, so competition may not arrive quickly. Right now, only one potential competitor is in early-stage development. The Italian company Recordati is running a phase 2 trial of a different eye drop called udonitrectag for stage 2 and stage 3 neurotrophic keratitis, with 45 study sites across North America and Europe. Phase 2 trials are still years away from producing a commercially available product, so Oxervate will likely remain the only approved option for the foreseeable future.
Cold Chain Logistics Add Real Cost
Oxervate isn’t something that can sit on a pharmacy shelf at room temperature. The drug requires an unbroken cold chain from manufacturer to patient, and the logistics are demanding.
Pharmacies must store the weekly cartons of vials in a freezer at or below -4°F (-20°C). When dispensed, the vials travel in insulated packs alongside a specialized delivery system kit. Once you receive them, you have five hours to get the cartons into your refrigerator, where they stay between 36°F and 46°F for up to 14 days. After opening a vial for your daily dose, you have just 12 hours before the remaining solution must be thrown away, whether you’ve used it all or not. The vials cannot be refrozen.
Every step of this process adds expense. Specialty pharmacies need dedicated freezer storage. Shipping requires temperature-controlled packaging with monitoring. And because each vial is single-use with a 12-hour window, there’s built-in waste. These aren’t trivial operational costs, and they get passed along in the drug’s price.
Insurance Coverage and Out-of-Pocket Reality
Most insurers do cover Oxervate, but not without hurdles. A representative policy from Johns Hopkins Health Plans illustrates what’s typical: you need to be at least 2 years old, have a documented diagnosis of stage 2 or stage 3 neurotrophic keratitis (meaning a persistent epithelial defect or corneal ulcer), and you must have already tried and failed at least one over-the-counter artificial tear product. Prior authorization is standard, and your ophthalmologist will need to submit clinical documentation.
Even with insurance approval, copays for specialty biologics can be substantial. Dompé offers a program called Connect to Care that includes a copay assistance option bringing the patient’s cost down to as low as $100 per fill. There’s also a patient assistance program for those who qualify based on financial need, which coordinates delivery and administration of the drug. If you’re facing a prescription for Oxervate, asking your prescriber’s office to connect you with these programs before filling is worth the phone call.
Why the Price Persists
Oxervate’s price is not the result of any single factor but the compounding of several. It’s a biologic, not a chemical compound, so manufacturing is inherently expensive. It treats a condition so rare that the total market of patients is tiny. It requires freezer storage, specialty shipping, and single-use vials that expire within hours of opening. It has no competitors and won’t for years. And it works well enough that there’s genuine clinical demand: patients treated with Oxervate were over four times more likely to achieve near-complete corneal healing at eight weeks than those on placebo, with most side effects being mild.
For the small number of people with neurotrophic keratitis who face the prospect of progressive corneal damage and potential vision loss, Oxervate is currently the only FDA-approved treatment that addresses the underlying nerve damage rather than just managing symptoms. That combination of clinical necessity and market exclusivity gives the manufacturer significant pricing power, and there’s little economic pressure to bring the cost down until a competitor reaches the market.